Skip to content

Clinical trials

Phase 2 Cardiomyopathy, Hypertrophic trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cardiomyopathy, Hypertrophic Phase: Phase 2 Clear all

34 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20061
20071
20112
20122
20131
20141
20151
20162
20182
20191
20204
20232
20242
20252
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed18
Recruiting5
Unknown status4
Terminated3
Active, not recruiting2
Not yet recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)6
Bristol-Myers Squibb2
Shandong Suncadia Medicine Co., Ltd.2
Amckaus PTY LTD.1
Array Biopharma, now a wholly owned subsidiary of Pfizer1
Carelon Research1
Charles University, Czech Republic1
China National Center for Cardiovascular Diseases1
Cytokinetics1
Edgewise Therapeutics, Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cardiomyopathy, Hypertrophic34
Cardiomyopathies3
Cardiomegaly2
Heart Diseases2
Heart Failure2
Hypertrophy2
Hypertrophy, Left Ventricular2
Acute Coronary Syndrome1
Arrhythmias, Cardiac1
Cardiomyopathy, Hypertrophic, Familial1

Trials

Showing 51 to 34 of 34. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.